The objective of the study is to evaluate, in a clinical trial, the efficacy of peri operative administration of long-acting inhaled ß-2 mimetics on the occurrence of postoperative pulmonary complications

Inclusion Criteria:

• Adult (>18 years)
• Lung cancer eligible for surgical management by lung resection (non-small cell lung carcinoma = NSCLC) by any route
• Naïve to long-term inhaled bronchodilator therapy
• High risk of post-operative pulmonary complications (Pre-operative FEV1 < 80%)

Exclusion Criteria:

• Patient refusal
• Pregnancy
• Emergency surgery
• Patient with a physiological status of WHO IV or ASA ≥ IV
• Asthma
• Patients treated with long-acting bronchodilators
• Severe heart failure (NYHA IV), unstable ischaemic heart disease (angina or recent infarction < 3 months), obstructive hypertrophic cardiomyopathy, subvalvular aortic stenosis, severe uncontrolled hypertension Recent stroke < 3 months
• High-grade unresponsive conductive disorders or unstable arrhythmia
• Thyrotoxicosis, pheochromocytoma
• Unbalanced diabetes
• Hypersensitivity to ß-2 mimetics or lactose
• Current participation in a trial of another drug therapy